
Sign up to save your podcasts
Or
Sleep disturbances, such as insomnia, sleep fragmentation, excessive daytime sleepiness, and REM sleep behavior disorder are common in people with Parkinson's disease (PD). Poor sleep quality can also impact other domains of function, including motor function. Prior research has shown that a type of photoreceptor cell in the retina, called melanopsin cells, provide the main light signals to the brain to initiate sleep, and function of these cells is impaired in PD. Dr. Beatix Feigl and her colleagues developed a novel light therapy intervention that selectively activates the melanopsin photoreceptor cells, and in this episode, she discusses the results of a recent randomized controlled trial evaluating the efficacy of this melanopsin photoreceptor-directed light therapy on sleep and circadian rhythm, as well as motor behaviors. She also discusses her earlier work on melanopsin cells that led to the development of standard measures to assess their function. Beatrix is an Ophthalmologist and an Associate Professor in the School of Biomedical Sciences and Center for Vision and Eye Research, as well as the Faculty of Health, at the Queensland University of Technology.
Mentioned in this episode:
August is Make-A-Will Month, which serves as a reminder of the importance of creating and updating your will. Use this moment to take control of your future and ensure your wishes are respected. Visit michaeljfox.org/plan to learn more and get started.
This podcast episode was part of a limited series created by The Michael J. Fox Foundation in 2023 and 2024 for clinicians and researchers in our audience. These episodes provide a deeper dive into exciting new scientific research in Parkinson’s disease, as well as innovative tools and valuable resources, through conversations with a variety of experts in the field. We hope you enjoy the conversation.
4.1
197197 ratings
Sleep disturbances, such as insomnia, sleep fragmentation, excessive daytime sleepiness, and REM sleep behavior disorder are common in people with Parkinson's disease (PD). Poor sleep quality can also impact other domains of function, including motor function. Prior research has shown that a type of photoreceptor cell in the retina, called melanopsin cells, provide the main light signals to the brain to initiate sleep, and function of these cells is impaired in PD. Dr. Beatix Feigl and her colleagues developed a novel light therapy intervention that selectively activates the melanopsin photoreceptor cells, and in this episode, she discusses the results of a recent randomized controlled trial evaluating the efficacy of this melanopsin photoreceptor-directed light therapy on sleep and circadian rhythm, as well as motor behaviors. She also discusses her earlier work on melanopsin cells that led to the development of standard measures to assess their function. Beatrix is an Ophthalmologist and an Associate Professor in the School of Biomedical Sciences and Center for Vision and Eye Research, as well as the Faculty of Health, at the Queensland University of Technology.
Mentioned in this episode:
August is Make-A-Will Month, which serves as a reminder of the importance of creating and updating your will. Use this moment to take control of your future and ensure your wishes are respected. Visit michaeljfox.org/plan to learn more and get started.
This podcast episode was part of a limited series created by The Michael J. Fox Foundation in 2023 and 2024 for clinicians and researchers in our audience. These episodes provide a deeper dive into exciting new scientific research in Parkinson’s disease, as well as innovative tools and valuable resources, through conversations with a variety of experts in the field. We hope you enjoy the conversation.
3,605 Listeners
12,588 Listeners
140 Listeners
1,879 Listeners
9,276 Listeners
224 Listeners
182 Listeners
28 Listeners
14,287 Listeners
27 Listeners
29 Listeners
5 Listeners
50 Listeners
96 Listeners
8 Listeners